We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

KYGA:LSEKerry Group Plc Class A Analysis

Data as of 2026-06-13 - not real-time

€76.60

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Kerry Group trades at €76.6, comfortably above its 20‑day SMA of €73.91 and the 200‑day SMA of €74.56, indicating short‑term price strength. The RSI sits at 63, bordering on overbought, while a bullish MACD histogram (+0.14) confirms upward momentum, though volume is on a decreasing trend, hinting at potential fatigue. Fundamentally, the stock carries a forward PE of 13.86 versus a trailing PE of 19.20, a solid gross margin of 51% and a healthy payout ratio of 33%, supporting the current dividend yield of 1.83%. However, the DCF‑derived fair value of €11.17 is dramatically lower than the market price, flagging a severe valuation gap despite a modest upside/downside estimate of 21% based on analyst targets. The company’s low beta (~0.06) and defensive consumer‑staples positioning mitigate market volatility, yet a 30‑day volatility of 28% and a max drawdown of 34% underscore inherent price swings. Overall, the blend of strong cash flows, sustainable dividends, and defensive sector exposure is offset by an apparent overvaluation and waning buying pressure.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price above short‑term SMAs but RSI nearing overbought
  • Bullish MACD yet decreasing volume
  • Potential short‑term price correction

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • Strong operating cash flow and sustainable dividend
  • Forward earnings growth improving PE multiple
  • Defensive consumer‑staples sector cushioning volatility

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Low beta and defensive positioning support stability
  • Valuation gap suggests limited upside unless price realigns
  • Consistent dividend payout enhances total return

Key Metrics & Analysis

Financial Health

Profit Margin9.74%
P/E Ratio19.2
ROE10.59%
ROA4.84%
Debt/Equity43.55
P/B Ratio2.1
Op. Cash Flow€755.5M
Free Cash Flow€304.5M

Technical Analysis

TrendNeutral
RSI63.0
Support€71.45
Resistance€77.25
MA 20€73.91
MA 50€71.20
MA 200€74.56
MACDBullish
VolumeDecreasing
Fear & Greed Index89.86

Valuation

Fair Value€11.17
Target Price€92.80
Upside/Downside21.15%
GradeOvervalued
TypeValue
Dividend Yield1.83%

Risk Assessment

Beta0.06
Volatility28.66%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.